The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K.
Radar 93 (high attention) · dilution pressure high · listing risk high · governance risk elevated · runway 12.8 mo · strongest signal: MVLS deficiency (Jul 20, 2026)
What would confirm: 424B5/8-K announcing an offering, ATM sales disclosed in next 10-Q, or Form 4 sales by insiders ahead of it.
What would prove it wrong: Non-dilutive cash event (asset sale, grant, milestone payment), OCF turning positive, or shelf withdrawn (RW).
Direction is stated for existing shareholders (▼ more shares / survival or listing risk; ▲ insiders or holders buying). It is a characterization of the filings, not a forecast or a recommendation.
Independent filings stitched into a thesis, each with what would confirm and what would prove it wrong.
The filings point to a discounted equity raise ahead — dilution for existing holders. Next thing to watch: a 424B or offering 8-K. Cash need (going-concern language) coexists with live selling machinery (registered direct, shelf effective, shelf filed, offering (424b)). Base case is a discounted raise; the question is when, not if.
Listing is at risk and the usual cures are constrained. Next thing to watch: a reverse-split proxy, a hearings-panel 8-K, or a Form 25. Exchange deficiency plus a structural reason cure is hard (sub-$5M float, negative equity, no cash, or a reverse split already used). Under Nasdaq's 2026 rules (one reverse split per 12 months; $5M MVLS floor with no cure period from Sept 2026) the usual escape hatches are narrower.
No note yet. Notes are written each morning for the top-ranked setups; Pro subscribers get them in full the same day.
Runway = liquidity ÷ monthly operating burn at the latest reported period · balance sheet 47 days old. A financing after the balance-sheet date is the main reason a figure can be stale — check the timeline below for offerings since then.
Last 30 days of filing signals plus current balance-sheet flags, newest first. ▼ pressure · ▲ support · hover a score for its components; every row links to the filing.
| Date | Signal | Evidence | Score |
|---|---|---|---|
| Aug 10, 2026 | ▼ Going-concern language | “going concern periodic” language in 10-Q (10-Q) filed 2026-08-10 filing | 33 |
| Aug 7, 2026 | ▼ Offering (424B) | 424B3 prospectus supplement 2026-08-07; 1 prior 424B filings in 12m filing | 28 |
| Aug 6, 2026 | ▼ Shelf effective | EFFECT notice 2026-08-06 filing | 21 |
| Jul 24, 2026 | ▼ Material agreement terminated | 8-K Item 1.02 filed 2026-07-24 (accepted 16:05 ET) filing | 34 |
| Jul 24, 2026 | ▼ Shelf filed | S-3 filed 2026-07-24 filing | 30 |
| Jul 24, 2026 | · Officer/director change | 8-K Item 5.02 filed 2026-07-24 (accepted 16:05 ET) filing | 24 |
| Jul 20, 2026 | ▼ MVLS deficiency | “mvls deficiency” language in 8-K (8-K) filed 2026-07-20 filing | 63 |
| Jul 20, 2026 | ▼ Exchange deficiency notice | 8-K Item 3.01 filed 2026-07-20 (accepted 16:00 ET) filing | 55 |
| Jul 20, 2026 | ▼ Delisting language | “delisting notice” language in 8-K (8-K) filed 2026-07-20 filing | 46 |
| Jul 20, 2026 | ▼ Registered direct | “rdo” language in 8-K (8-K) filed 2026-07-20 filing | 34 |
| Jun 30, 2026 | ▼ Share count +25% | Shares outstanding 3,977,443 (2026-05-12) -> 11,977,443 (2026-08-05), +201% filing | 45 |
| Jun 30, 2026 | ▼ Near $5M MVLS floor | Public float $4,787,341 (as of 2025-06-30) vs $5M Nasdaq MVLS floor; needs price x shares confirmation filing | 27 |
VIVS VivoSim Labs, INC. · HCWB HCW Biologics Inc. · CYCU Cycurion, Inc. · BIAF bioAffinity Technologies, In · VSEE VSEE HEALTH, INC. · OTLK Outlook Therapeutics, Inc. · screener →